Neurodevelopmental and environmental hypotheses of negative symptoms of schizophrenia

BMC Psychiatry

Frédéric Limosin¹ 

[1] Department of Adult and Geriatric Psychiatry, Hôpitaux Universitaires Paris Ouest (AP-HP), Hôpital Corentin-Celton, 4, parvis Corentin-Celton, 92133 Issy-les-Moulineaux, France

关键词: Neurodevelopmental hypothesis;    Environment;    Negative symptoms;    Schizophrenia;   

Others  :  1123685
DOI  :  10.1186/1471-244X-14-88

 received in 2013-11-12, accepted in 2014-03-18,  发布年份 2014

【 摘 要 】

The negative symptoms of schizophrenia, avolition, alogia, apathy and impaired or nonexistent social functioning, are strongly correlated with the progressive course and long-term prognosis of the disease, undermining the patient’s ability to integrate socially, interpersonal skills and quality of life. At a time when new drug strategies are being developed, a better understanding of the etiology and pathogenesis underpinning the occurrence of negative symptoms constitutes an essential prerequisite for real therapeutic advances. Approaching this vulnerability from the neurodevelopmental perspective is especially pertinent with regard to the experimental studies conducted in animals. Several models have been put forward, involving a variety of topics such as the deleterious impact of a prenatal infection or of early maternal deprivation on brain development, or else the consequences of trauma and abuse suffered during childhood. These various models are based on biological abnormalities that could guide the identification of new therapeutic targets. They notably include the hyperreactivity of the hypothalamic-pituitary-adrenal axis and dysfunction of corticostriatal glutamatergic transmission. As such, in the traumagenic model, which associates neurodevelopmental and neurodegenerative processes, the dysfunction of corticostriatal glutamatergic transmission, by reducing the tonic dopamine release, could be the cause of an increase in the phasic dopamine release linked to stress. This excessive phasic response to stress may induce cerebral damage by increasing excitotoxicity and oxidative stress.

【 授权许可】

   
2014 Limosin; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Sullivan PF, Kendler KS, Neale MC: Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatr 2003, 60:1187-1192.
• [2]Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF, Hultman CM: Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 2009, 373:234-239.
• [3]Cantor-Graae E, Selten JP: Schizophrenia and migration: a meta-analysis and review. Am J Psychiatry 2005, 162:12-24.
• [4]Oher FJ, Demjaha A, Jackson D, Morgan C, Dazzan P, Morgan K, Boydell J, Doody GA, Murray RM, Bentall RP, Jones PB, Kirkbride JB: The effect of the environment on symptom dimensions in the first episode of psychosis: a multilevel study. Psychol Med 2014, 21:1-12.
• [5]Ellett L, Freeman D, Garety PA: The psychological effect of an urban environment on individuals with persecutory delusions: the Camberwell walk study. Schizophr Res 2008, 99:77-84.
• [6]Zugno AI, de Miranda IM, Budni J, Volpato AM, Luca RD, Deroza PF, de Oliveira MB, Heylmann AS, da Rosa Silveira F, Wessler P, Antunes Mastella G, Cipriano AL, Quevedo J: Effect of maternal deprivation on acetylcholinesterase activity and behavioral changes on the ketamine-induced animal model of schizophrenia. Neuroscience 2013, 248C:252-260.
• [7]De Hert M, Wampers M, Jendricko T, Franic T, Vidovic D, De Vriendt N, Sweers K, Peuskens J, Van Winkel R: Effects of cannabis use on age at onset in schizophrenia and bipolar disorder. Schizophr Res 2011, 126:270-276.
• [8]Arseneault L, Cannonn M, Witton J, Murray RM: Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatr 2004, 184:110-117.
• [9]Yolken RH, Torrey EF: Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev 1995, 8:131-145.
• [10]Menninger KA: The schizophrenia syndrome as a product of acute infectious disease. Arch Neurol Psychiatr 1928, 20:464-481.
• [11]Davies G, Welham J, Chant D, Torrey EF, McGrath J: A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. Schizophr Bull 2003, 29:587-593.
• [12]Kay RW: Schizophrenia and season of birth: relationship to geomagnetic storms. Schizophr Res 2004, 66:7-20.
• [13]Torrey EF, Miller J, Rawlings R, Yolken RH: Seasonality of births in schizophrenia and bipolar disorder: a review of the literature. Schizophr Res 1997, 28:1-38.
• [14]Goldberg AE, Newlin DB: Season of birth and substance abuse: findings from a large national sample. Alcohol Clin Exp Res 2000, 24:774-780.
• [15]Cannon M, Jones PB, Murray RM: Obstetric complications and schizophrenia: historical and meta-analytic review. Am J Psychiatr 2002, 159:1080-1092.
• [16]Verdoux H, Sutter AL: Perinatal risk factors for schizophrenia: diagnostic specificity and relationships with maternal psychopathology. Am J Med Genet 2002, 114:898-905.
• [17]Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellachich LA: Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatr 2005, 162:79-91.
• [18]Limosin F, Rouillon F, Payan C, Cohen JM, Strub N: Prenatal exposure to influenza as a risk factor for adult schizophrenia. Acta Psychiatr Scand 2003, 107:331-335.
• [19]Machón RA, Mednick SA, Huttunen MO: Adult major affective disorder after prenatal exposure to an influenza epidemic. Arch Gen Psychiatr 1997, 54:322-328.
• [20]Wright P, Donaldson PT, Underhill JA, Choudhuri K, Doherty DG, Murray RM: Genetic association of the HLA DRB1 gene locus on chromosome 6p21.3 with schizophrenia. Am J Psychiatr 1996, 153:1530-1533.
• [21]York GK, Steinberg DA: An Introduction to the Life and Work of John Hughlings Jackson. Med Hist Suppl 2007, 26:3-34.
• [22]Kring AM, Gur RE, Blanchard JJ, Horan WP, Reise SP: The Clinical Assessment Interview for Negative Symptoms (CAINS): final development and validation. Am J Psychiatry 2013, 170:165-172.
• [23]Marder SR, Alphs L, Anghelescu IG, Arango C, Barnes TR, Caers I, Daniel DG, Dunayevich E, Fleischhacker WW, Garibaldi G, Green MF, Harvey PD, Kahn RS, Kane JM, Keefe RS, Kinon B, Leucht S, Lindenmayer JP, Malhotra AK, Stauffer V, Umbricht D, Wesnes K, Kapur S, Rabinowitz J: Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res 2013, 150:328-333.
• [24]Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT: A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatr 2001, 58:165-171.
• [25]Shivashankar S, Telfer S, Arunagiriraj J, McKinnon M, Jauhar S, Krishnadas R, McCreadie R: Has the prevalence, clinical presentation and social functioning of schizophrenia changed over the last 25 years? Nithsdale schizophrenia survey revisited. Schizophr Res 2013, 146:349-356.
• [26]Kety SS, Rosenthal D, Wender PH, Schulsinger R, Jacobsen B: Mental illness in the biological and adoptive families of adopted individuals who have become schizophrenic. Behav Gen 1976, 6:219-225.
• [27]Dworkin RH, Lenzenweger MF: Symptoms and the genetics of schizophrenia: implications for diagnosis. Am J Psychiatr 1984, 141:1541-1546.
• [28]Dworkin RH, Lenzenweger MF, Moldin SO, Skillings GF, Levick SE: A multidimensional approach to the genetics of schizophrenia. Am J Psychiatr 1988, 145:1077-1083.
• [29]Kendler KS, McGuire M, Gruenberg AM, Walsh D: Schizotypal symptoms and signs in the Roscommon family study: their factor structure and familial relationship with psychotic and affective disorders. Arch Gen Psychiatr 1995, 52:296-303.
• [30]Brown AS, Vinogradov S, Kremen WS, Poole JH, Deicken RF, Penner JD, Mckeague IW, Kochetkova A, Kern D, Schaefer CA: Prenatal exposure to maternal infection and executive dysfunction in adult schizophrenia. Am J Psychiatr 2009, 166:683-690.
• [31]Brown AS, Deicken RF, Vinogradov S, Kremen WS, Poole JH, Penner JD, Kochetkova A, Kern D, Schaefer CA: Prenatal infection and cavum septum pellucidum in adult schizophrenia. Schizophr Res 2009, 108:285-287.
• [32]D’Amato T, Dalery J, Rochet T, Terra JL, Marie-Cardine M: Saisons de naissance et psychiatrie: etude rétrospective d’une population hospitalière. Encéphale 1991, 17:67-71.
• [33]Hsieh HH, Khan MH, Atwal SS, Chu CC: Seasons of birth and sub-types of schizophrenia. Br J Psychiatr 1986, 149:125.
• [34]D’Amato T, Verdoux H: Facteurs environnementaux et risque de schizophrénie: déséquilibre saisonnier des naissances et autres facteurs de risque. In La schizophrénie, recherches actuelles et perspectives. Edited by Dalery J, D’Amato T. Paris: Masson; 1995:63-92.
• [35]Watson CG, Kucala T, Tilleskjor C, Jacobs L: Schizophrenic birth seasonality in relation to the incidence of infectious diseases and temperature extremes. Arch Gen Psychiatr 1984, 41:85-90.
• [36]Meyer U, Feldon J, Schedlowski M, Yee BK: Immunological stress at the maternal-foetal interface: a link between neurodevelopment and adult psychopathology. Brain Behav Immun 2006, 20:378-388.
• [37]Meyer U, Nyffeler M, Yee BK, Knuesel I, Feldon J: Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. Brain Behav Immun 2008, 22:469-486.
• [38]Bitanihirwe BKY, Peleg-Raibstein D, Mouttet F, Feldon J, Meyer U: Late prenatal immune activation in mice leads to behavioral and neurochemical abnormalities relevant to the negative symptoms of schizophrenia. Neuropsychopharmacology 2010, 35:2462-2478.
• [39]Meaney MJ, Viau V, Bhatnagar S, Betito K, Iny LJ, O’Donnell D, Mitchell JB: Cellular mechanisms underlying the development and expression of individual differences in the hypothalamic-pituitary-adrenal stress response. J Steroid Biochem Mol Biol 1991, 39:265-274.
• [40]Meaney MJ, Bhatnagar S, Diorio J, Larocque S, Francis D, O’Donnell D, Shanks N, Sharma S, Smythe J, Viau V: Molecular basis for the development of individual differences in the hypothalamic-pituitary-adrenal stress response. Cell Mol Neurobiol 1993, 13:321-347.
• [41]Weiss IC, Feldon J: Environmental animal models for sensorimotor gating deficiencies in schizophrenia: a review. Psychopharmacology (Berl) 2001, 156:305-326.
• [42]Aisa B, Tordera R, Lasheras B, Del Río J, Ramírez MJ: Cognitive impairment associated to HPA axis hyperactivity after maternal separation in rats. Psychoneuroendocrinology 2007, 32:256-266.
• [43]Aisa B, Tordera R, Lasheras B, Del Río J, Ramírez MJ: Effects of maternal separation on hypothalamic-pituitary-adrenal responses, cognition and vulnerability to stress in adult female rats. Neuroscience 2008, 154:1218-1226.
• [44]Takase K, Yamamoto Y, Yagami T: Maternal deprivation in the middle of a stress hyporesponsive period decreases hippocampal calcineurin expression and causes abnormal social and cognitive behaviours in adult male Wistar rats: relevance to negative symptoms of schizophrenia. Behav Brain Res 2012, 232:306-315.
• [45]Rodnick E, Goldstein M, Lewis J, Doane J: Parental communication style, affect, and role as precursors of offspring schizophrenia-spectrum disorders. In Children at risk for schizophrenia. Edited by Watt E, Anthony L, Wynne J. New York: Rolf; 1984.
• [46]Ross CA, Anderson G, Clark P: Childhood abuse and the positive symptoms of schizophrenia. Hosp Community Psychiatr 1994, 45:489-491.
• [47]Read J, Perry BD, Moskowitz A, Connolly J: The contribution of early traumatic events to schizophrenia in some patients: a traumagenic neurodevelopmental model. Psychiatr 2001, 64:319-345.
• [48]Andersen SL, Thompson AT, Rutstein M, Hostetter JC, Teicher MH: Dopamine receptor pruning in prefrontal cortex during the periadolescent period in rats. Synapse 2000, 37:167-169.
• [49]McGlashan TH, Hoffman RE: Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatr 2000, 57:637-648.
• [50]Altamura AC, Pozzoli S, Fiorentini A, Dell’osso B: Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology. Progr Neuropsychopharmacol Biol Psychiatr 2013, 42:63-70.
• [51]Davis MC, Horan WP, Marder SR: Psychopharmacology of the negative symptoms: current status and prospects for progress. Eur Neuropsychopharmacol 2013. doi:10.1016/j.euroneuro.2013.10.010. [Epub ahead of print]
• [52]Klingberg S, Wölwer W, Engel C, Wittorf A, Herrlich J, Meisner C, Buchkremer G, Wiedemann G: Negative symptoms of schizophrenia as primary target of cognitive behavioral therapy: results of the randomized clinical TONES study. Schizophr Bull 2011, 37(suppl. 2):S98-S110.